CARDAMYST

Launch

etripamil

NDANASALSPRAY
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100

Mechanism of Action

L-type calcium influx inhibitor (slow channel blocker or calcium ion antagonist). Etripamil exerts its pharmacologic effect by modulating the influx of ionic calcium across the cell membrane of the AV nodal cells as well as arterial smooth muscles and contractile myocardial cells. By interrupting…

Loss of Exclusivity

LOE Date
Jul 15, 2042
199 months away
Patent Expiry
Jul 15, 2042
Exclusivity Expiry
Dec 12, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
10010522
Jun 19, 2028
U-38
10010523
Jun 19, 2028
Substance
9227918
Jun 19, 2028
Product
9463179
Jun 19, 2028
U-4370
10117848
Apr 13, 2036
Product
U-4370